Clinical trial for Respiratory Tract Diseases
Official title Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
ClinicalTrials.gov ID: NCT02735707
What this study is testing
What is Ceftriaxone?
Ceftriaxone is an antibiotic being studied in a trial to see if it helps treat severe pneumonia in the ICU. It is designed to fight bacterial infections by stopping bacteria from building their cell walls.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out which treatments help patients with severe lung infections recover better. It also serves as a flexible system to test new therapies during respiratory outbreaks like COVID-19.
- Who it's for
- The study is looking for adults who are in the intensive care unit with severe pneumonia, influenza, or COVID-19.
- What's involved
- Participants will be randomly assigned to receive one of several different treatments or standard care. They will undergo regular medical tests and monitoring to track their health.
- Time commitment
- The duration and specific visit schedule are not detailed in the provided text.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 28 and older
You may be able to join if
- The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and
You likely can't join if
- All Platform inclusion criteria are met
- None of the Platform exclusion criteria are met
- Domain-specific eligibility criteria are met
- Hospitalised patient
- Acute respiratory tract infection
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending...
See the full eligibility criteria
- The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and
- All Platform inclusion criteria are met
- None of the Platform exclusion criteria are met
- Domain-specific eligibility criteria are met
- Hospitalised patient
- Acute respiratory tract infection
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital within the next 24 hours
- Previous participation in this REMAP within the last 90 days DOMAIN-SPECIFIC ELIGIBILITY CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
The study team makes the final eligibility decision.
Where it is enrolling
- Jacksonville, Florida, United States
- Chicago, Illinois, United States
- Ann Arbor, Michigan, United States
- New York, New York, United States
- Columbus, Ohio, United States
- Portland, Oregon, United States
- Pittsburgh, Pennsylvania, United States
- Canberra, Australian Capital Territory, Australia
- Bankstown, New South Wales, Australia
- Blacktown, New South Wales, Australia
- Campbelltown, New South Wales, Australia
- Caringbah, New South Wales, Australia
- Concord, New South Wales, Australia
- Dubbo, New South Wales, Australia
- Frenchs Forest, New South Wales, Australia
- Kingswood, New South Wales, Australia
- Kogarah, New South Wales, Australia
- Liverpool, New South Wales, Australia
- Newcastle, New South Wales, Australia
- Sydney, New South Wales, Australia
+ 158 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 28 days and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Jacksonville, Florida, United States; Chicago, Illinois, United States; Ann Arbor, Michigan, United States; New York, New York, United States; Columbus, Ohio, United States; Portland, Oregon, United States and 172 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.